Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
$481.59
-$0.58(-0.25%)
At close: 4:00 PM EST
$481.59
-$0.58(-0.25%)
Day’s Range― - ―
52-Week Range$205.87 - $495.55
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.06M
Market Cap
$63.13B
Enterprise Value$42.48B
Total Cash (Recent Filing)$2.86B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Feb 12, 2026EPS Estimate
1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.84
Shares Outstanding131,079,010
10 Day Avg. Volume966,015
30 Day Avg. Volume1,056,737
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue17.25
Enterprise Value/Gross Profit20.63
Enterprise Value/Ebitda-248.52
Forecast
1Y Price Target
$478.96Price Target Upside-0.55% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
FDA Guidance BenefitsAlnylam Pharmaceuticals stands to benefit from the FDA's draft guidances, which broaden flexibility in clinical trial design and expand the role of real-world evidence across genetic medicines.
Price Target IncreaseThe price target for Alnylam Pharmaceuticals is raised to $475, reflecting a positive outlook on the stock.
Sales PerformanceMonthly sales analysis suggests upside to 3Q25 Amvuttra estimates, indicating strong sales performance.
Bears Say
Valuation ConcernsQuestions on ALNY’s valuation at current levels and the upside from here indicate concerns about the sustainability of the launch momentum.
Zilebesiran LimitationsPhysicians were relatively underwhelmed by the magnitude of effect in the overall population for zilebesiran in hypertension, indicating potential limitations.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $205.87 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $63.13B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Feb 12, 2026 which is in 105 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Oct 30, 2025. The company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $0.561 by $1.279.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Overvalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.61.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 131,079,010 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.84 in its last earnings report, beating expectations of $0.561. Following the earnings report the stock price went up 15.433%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$478.96 (-0.55% Downside)
$478.96 (-0.55% Downside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 162.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.16%
12-Months-Change
Fundamentals
Return on Equity
-257.82%
Trailing 12-Months
Asset Growth
13.88%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies based on RNA interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a leader in the RNAi therapeutics sector, aiming to treat a range of diseases by silencing specific genes. The company's core products include Onpattro (patisiran), which is approved for the treatment of hereditary transthyretin-mediated amyloidosis, and several other investigational therapies targeting various genetic disorders and conditions.
ALNY Company Deck
ALNY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Alnylam Q2 2025 highlighted strong commercial performance and successful product launches, particularly for AMVUTTRA in ATTR-CM, leading to an upgraded financial outlook. Despite some decreases in collaboration revenue and product sales margins, the overall sentiment remains highly positive due to the robust growth and positive future guidance.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$478.96
▼(-0.55% Downside)
Technical Analysis
Ownership Overview
0.42% Insiders
48.94% Mutual Funds
0.29% Other Institutional Investors
33.99% Public Companies and
Individual Investors